Cargando…

Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report

BACKGROUND & OBJECTIVES: With pioglitazone ban and subsequent revoking in India along with varying regulatory decisions in other countries, it was decided to carry out a systematic review on its safety, efficacy and drug utilization in patients with type 2 diabetes mellitus (T2DM) in India and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pai, Sarayu A., Kshirsagar, Nilima A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393077/ https://www.ncbi.nlm.nih.gov/pubmed/28361819 http://dx.doi.org/10.4103/ijmr.IJMR_650_15

Ejemplares similares

Systematic review of drug utilization studies & the use of the drug classification system in the WHO-SEARO Region
por: Bachhav, Sagar S., et al.
Publicado: (2015)

Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study
por: Balaji, Vijayam
Publicado: (2013)

Pioglitazone: Indian perspective
por: Shukla, Rishi, et al.
Publicado: (2011)

European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation
por: Zoeller, R Thomas, et al.
Publicado: (2023)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency
por: Chatzopoulou, Sevasti, et al.
Publicado: (2020)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

Antiviral Potential of Selected Indian Medicinal (Ayurvedic) Plants Against Herpes Simplex Virus 1 and 2
por: Jadhav, Priyanka, et al.
Publicado: (2012)

Rational use of medicines: Cost consideration & way forward
por: Kshirsagar, Nilima A.
Publicado: (2016)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

A systematic review of standard treatment guidelines in India
por: Koli, Paresh Girdharlal, et al.
Publicado: (2019)

An Indian "Medical Agency."
Publicado: (1867)

Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates
por: Shafiq, Nusrat, et al.
Publicado: (2017)

Post-marketing safety signals: Challenges in regulatory decisions, communication & impact evaluation in developing countries
por: Kshirsagar, Nilima
Publicado: (2017)

Legislation and standards of the European Agency for Safety and Health at Work
por: European Agency for Safety and Health at Work. Bilbao
Publicado: (2000)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Efficacy and safety of traditional Chinese medicine in the treatment of osteonecrosis of the femoral head
por: Ouyang, Wensi, et al.
Publicado: (2023)

Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
por: Wiedermann, Christian J., et al.
Publicado: (2017)

Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
por: Lenić, Ines, et al.
Publicado: (2019)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research
por: Ferran, Jean-Marc, et al.
Publicado: (2019)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
por: Nicotera, Giuseppe, et al.
Publicado: (2019)

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
por: Satirapoj, Bancha, et al.
Publicado: (2018)

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
por: Gupta, Sunil, et al.
Publicado: (2015)

Overview of the European Medicines Agency's Development of Product‐Specific Bioequivalence Guidelines
por: Sullivan, Jane O', et al.
Publicado: (2018)

Biomarker Qualification at the European Medicines Agency: A Look Under the Hood
por: Berman, Steven, et al.
Publicado: (2022)

The efficacy of pioglitazone for renal protection in diabetic kidney disease
por: Ho, Chao-Chung, et al.
Publicado: (2022)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers
por: Malottki, Kinga, et al.
Publicado: (2014)

Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
por: Jamieson, Lisa, et al.
Publicado: (2015)

EHPnet: European Chemicals Agency
por: Dooley, Erin E.
Publicado: (2008)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
por: Lythgoe, Mark P., et al.
Publicado: (2021)

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
por: Forst, T, et al.
Publicado: (2014)

Children’s Behavioral Agency within Families in the Context of Migration: A Systematic Review
por: Deng, Zihong, et al.
Publicado: (2021)

Access to regulatory data from the European Medicines Agency: the times they are a-changing
por: Wieseler, Beate, et al.
Publicado: (2012)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t88todq9nbb46i8bhbr28c3qh2